265 related articles for article (PubMed ID: 10213229)
41. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
42. Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Iyengar RV; Pawlik CA; Krull EJ; Phelps DA; Burger RA; Harris LC; Potter PM; Danks MK
Cancer Res; 2001 Apr; 61(7):3045-52. PubMed ID: 11306486
[TBL] [Abstract][Full Text] [Related]
43. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
Gutova M; Najbauer J; Chen MY; Potter PM; Kim SU; Aboody KS
Curr Stem Cell Res Ther; 2010 Sep; 5(3):273-6. PubMed ID: 19951251
[TBL] [Abstract][Full Text] [Related]
46. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Kaneda N; Nagata H; Furuta T; Yokokura T
Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
[TBL] [Abstract][Full Text] [Related]
47. Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Wadkins RM; Potter PM; Vladu B; Marty J; Mangold G; Weitman S; Manikumar G; Wani MC; Wall ME; Von Hoff DD
Cancer Res; 1999 Jul; 59(14):3424-8. PubMed ID: 10416605
[TBL] [Abstract][Full Text] [Related]
48. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.
Tanimoto K; Kaneyasu M; Shimokuni T; Hiyama K; Nishiyama M
Pharmacogenet Genomics; 2007 Jan; 17(1):1-10. PubMed ID: 17264798
[TBL] [Abstract][Full Text] [Related]
49. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Wu MH; Yan B; Humerickhouse R; Dolan ME
Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
[TBL] [Abstract][Full Text] [Related]
50. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
[TBL] [Abstract][Full Text] [Related]
51. Human neural stem cell tropism to metastatic breast cancer.
Zhao D; Najbauer J; Annala AJ; Garcia E; Metz MZ; Gutova M; Polewski MD; Gilchrist M; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2012 Feb; 30(2):314-25. PubMed ID: 22084033
[TBL] [Abstract][Full Text] [Related]
52. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
53. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
54. Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Liu P; Ewis HE; Tai PC; Lu CD; Weber IT
J Mol Biol; 2007 Mar; 367(1):212-23. PubMed ID: 17239398
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
[TBL] [Abstract][Full Text] [Related]
56. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
57. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
Wagner LM; Guichard SM; Burger RA; Morton CL; Straign CM; Ashmun RA; Harris LC; Houghton PJ; Potter PM; Danks MK
Cancer Res; 2002 Sep; 62(17):5001-7. PubMed ID: 12208753
[TBL] [Abstract][Full Text] [Related]
59. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
60. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
